49 patents
Utility
Anti-viral Compounds
18 Jan 24
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
Filed: 5 Jul 23
Utility
Pyrrole Compounds
7 Dec 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany, Raymond F. Schinazi, Franck Amblard, Leda Bassit
Filed: 22 Aug 23
Utility
Modified Gapmer Oligomers and Methods of Use Thereof
30 Nov 23
The disclosure includes antisense oligonucleotides (ASOs), including gapmer ASOs, and methods of making and using the same.
Leonid Beigelman, Vivek Kumar Rajwanshi, Laxman Eltepu, Saul Martinez Montero, Jin Hong
Filed: 16 Mar 23
Utility
Bicyclic Compounds
30 Nov 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David McGowan, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
Filed: 17 Jul 23
Utility
Bicyclic Compounds
23 Nov 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David McGowan, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
Filed: 18 Apr 23
Utility
Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
16 Nov 23
Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 28 Jul 23
Utility
Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
19 Oct 23
Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 29 Nov 22
Utility
MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF
25 May 23
Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 7 Sep 22
Utility
Anti-viral Compounds
4 May 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Dorothée Alice Marie-Eve Bardiot, Koen Vandyck, Sandro Boland, Antitsa Dimitrova Stoycheva, Arnaud Didier Marie Marchand, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman
Filed: 14 Sep 22
Utility
Anti-viral Compounds
23 Mar 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Koen Vandyck, Dorothée Alice Marie-Eve Bardiot, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Sandro Boland, Arnaud Didier Marie Marchand
Filed: 6 Jul 22
Utility
Methods and Compositions for Targeting PD-L1
2 Mar 23
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction.
Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Jerome Deval, Cheng Liu, Qingling Zhang
Filed: 12 Aug 21
Utility
Bicyclic Compounds
16 Feb 23
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson, David McGowan, Yannick Debing
Filed: 15 Jun 22
Utility
Methods and Compositions for Targeting PD-L1
2 Feb 23
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction.
Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Cheng Liu, Jerome Deval, David McGowan
Filed: 15 Jun 22
Utility
Methods and Compositions for Targeting PD-L1
5 Jan 23
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction.
Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Antitsa Dimitrova Stoycheva, Francois Gonzalvez, Jerome Deval, Cheng Liu
Filed: 19 May 21
Utility
SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES
1 Dec 22
The present invention is in the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease.
Leonid BEIGELMAN, Antitsa STOYCHEVA, Aneerban BHATTACHARYA, David Bernard SMITH, Rajendra K. PANDEY, Saul Martinez MONTERO, Vivek Kumar RAJWANSHI, Jin HONG
Filed: 9 Apr 21
Utility
Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
17 Nov 22
Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 5 Mar 21
Utility
Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
9 Jun 22
Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof.
Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
Filed: 15 Feb 22
Utility
Tricyclic Compounds
2 Jun 22
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Yannick Debing, Pierre Jean-Marie Bernard Raboisson
Filed: 22 Nov 21
Utility
Conjugates of S-antigen Transport Inhibiting Oligonucleotide Polymers Having Enhanced Liver Targeting
26 May 22
Disclosed herein is an oligonucleotide conjugate or complex thereof, comprising a modified oligonucleotide having sequence independent antiviral activity against hepatitis B, a liver targeting agent, and a linker connecting the liver targeting agent to a 3′ end and/or a 5′ end of the modified oligonucleotide or complex thereof.
Leonid Beigelman, Megan Elizabeth Fitzgerald, Rajendra Pandey, Jin Hong, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt
Filed: 18 Nov 21
Utility
Oxindoles and Methods of Use Thereof
12 May 22
David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
Filed: 5 Nov 21